Abstract
AbstractMethodological advances in the HCT field have increased the population of survivors worldwide. However, HCT is associated with significant morbidity that impairs survivors’ recovery and adversely affects their quality of life (QoL).
Publisher
Springer International Publishing
Reference19 articles.
1. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–76.
2. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11:570–9.
3. Cella D, Riley W, Stone A, et al. The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2006. J Clin Epidemiol. 2010;63:1179–94.
4. Choi SW, Podrabsky R, McKinney N, et al. PROsetta Stone ® methodology: a Rosetta stone for patient reported outcomes. Chicago, IL: Department of Medical Social Sciences, Feinberg School of Medicine, Northwestern University; 2012.
5. Hinds PS, Nuss SL, Ruccione KS, et al. PROMIS pediatric measures in pediatric oncology: valid and clinically feasible indicators of patient-reported outcomes. Pediatr Blood Cancer. 2013;60:402–8.